In 1Q 2017 release, MannKind Corporation (NASDAQ:MNKD) posted revenue of $3 million, of which, revenue of $1.2 million was from Afrezza. The second part of the revenue came from the sale of bulk supplies. The company posted a net loss of $16.3 million compared to net loss of $24.87 million in 1Q 2016, however the question remains is it good enough for the firm.
In 1Q2017, the sales of Afrezza came at $1.2 million, while there were no comparable sales, a year earlier. On contrary, MannKind has shown some improvement on the cash position side, which has increased to $48 million as of the close of Q1 2017 from $22.9 million in December.
This increase in cash position can be accredited to the payment of around $30 million from Sanofi, and also to proceeds received against sale of a building. Now, with the Sanofi receivable removed from the books, the balance sheet has far less assets. MannKind is selling off its assets to get the required funds.
Here, it remains to understand the reason behind company selling so much of its bulk insulin. There are experts in the market who see it is as a big concern as clearly the sales numbers are well beyond the expectations. In Q4 2017, the company followed the same approach and sold bulk insulin to generate revenue of $10.2 million. In that respective quarter the insulin was given to Sanofi under the finalized deal.
To conclude, MannKind’s sales initiatives are leading nowhere. Revenue have thus far disappointed in 2017, while the company is looking for different ways to generate cash. There are no receivables noted on the books this reported quarter.
In the last trading session, the stock price of MannKind jumped more than 15% to close the day at $1.22. After the recent surge, the market cap of firm stands at 116.08 million.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.